When Arkansas banned PBMs from owning pharmacies, legislators cited a crisis: Independent pharmacies were closing at alarming rates. But were they?
We are all familiar with the natural churn of business. Retail stores open and close, sometimes because they struggle and sometimes because the market evolves. Big-box chains displaced local shops; online retail reshaped foot traffic; streaming made video and music stores obsolete. Across sectors, closures occur for many reasons but do not all carry the same meaning. Pharmacies fit this pattern as well, yet public discussion often treats every pharmacy closure as a crisis or a sign of systemic distress. The reality is more complicated.
Simple counts of pharmacy closures are frequently used to illustrate trends, and these statistics are often linked to a single explanation — usually, reimbursement pressure. But closures can result from many different circumstances, and the risk of viewing all of them through a single lens is to misunderstand what is actually happening — and why.
Missing from most discussions is a basic analytical distinction: what type of closure occurred, and why. The mechanism of exit describes the type of closure, such as whether a pharmacy actually ceased operating or merely changed hands. The drivers explain why that event occurred. In practice, pharmacy exits tend to fall into three broad categories: closures driven by business distress; life-cycle exits such as retirement, illness, or death; or prosperity exits — early retirement or sale following years of successful operation. Other drivers may include regulatory or enforcement actions, as well as broader market conditions. Without separating mechanisms and drivers, closure statistics collapse fundamentally different events into a single number.
Ownership transitions vs. true closures
Administrative datasets fail to distinguish between an ownership transition and a permanent closure, yet the difference is essential. An ownership transition occurs when a pharmacy changes hands — whether through retirement, acquisition by a chain, or a career change — but continues to serve the community. Chains often acquire thriving independent pharmacies for their strategic locations or established customer bases, triggering administrative resets — a new National Provider Identifier (NPI) or new National Council for Prescription Drug Programs (NCPDP) or Drug Enforcement Administration (DEA) numbers — that make these transactions indistinguishable from failures in closure data. These events look identical to permanent closures in the data, but they represent fundamentally different dynamics.
Consider a common scenario: A 68-year-old pharmacist who has owned her independent pharmacy for 35 years sells to a regional chain and retires. The old DEA and NPI numbers deactivate. The new owner registers with new identifiers. In administrative datasets, this appears as a closure and a new opening. In closure counts used in advocacy or policy debates, it often appears only as a loss. In reality, the community pharmacy continues serving patients with little or no interruption.
A permanent closure occurs when pharmacy services cease entirely. This may indicate financial distress, an unsustainable business model, or external challenges such as competition or local economic decline. True exits may be genuine losses to communities, though not always — as part of location rationalization, chains may couple closures with new openings elsewhere or shift business to other locations. Absent this distinction, the public conversation overstates how many stores are disappearing and the impact on communities.
Importantly, even among true exits, not all closures imply failure. Some reflect strategic location rationalization by small chains or file–buy transactions, in which a another pharmacy acquires a pharmacy’s prescription files and associated patient relationships, enabling continued dispensing to those patients even as the physical location exits the market. These events represent real location exits, but not necessarily business distress.
Urban and rural pharmacy closures tell different stories
The distinction between ownership transitions and true closures plays out differently across geographies. In urban and suburban areas with dense commercial infrastructure, ownership transitions are more common. Pharmacies in these markets are more likely to attract buyers — chains expanding their footprint or pharmacists looking to acquire a viable business. These transitions often involve administrative deactivation of identifiers, so they appear as closures even though the pharmacy continues to operate under new management. Operational gaps are often due to renovations and other changes during the changeover.
Rural areas face a different reality. True closures are more prevalent in economically strained communities where thin margins, smaller customer bases, and long supply chains make operations difficult. When a rural pharmacy closes, a buyer is far less likely to emerge, and communities often lose access. Not all rural closures, however, stem from financial distress. For instance, a pharmacist may be nearing the end of a long career. Life-cycle exits — age-related retirement, health-driven early retirement, or death — are not economic failures.
Conflating all closure events obscures these critical differences. Urban closure counts may primarily reflect ownership churn rather than loss of services, while rural statistics may mix genuine access crises with voluntary exits. Distinguishing between administrative transition and service loss is essential for accurate interpretation and effective policy responses.
How undifferentiated closure counts shape policy narratives
The ambiguity in closure data creates opportunities for stakeholder groups to advance particular narratives. Independent pharmacy advocates prominently point to aggregate closure counts, arguing that reimbursement pressures from PBMs threaten community pharmacy access. These claims gained significant traction during the Biden administration.
In July 2024 and January 2025, the Federal Trade Commission released two interim reports that emphasized how PBM practices were “squeezing independent pharmacies” through “unfair, arbitrary, and harmful contractual terms.” The first report noted that “between 2013 and 2022, about ten percent of independent retail pharmacies in rural America closed” and linked these closures directly to PBM contracting practices. This framing treated pharmacy closures as evidence of anticompetitive behavior and market failure, rather than as events requiring differentiation between distress and transition.
State legislatures embraced similar narratives. Arkansas’s first-in-the-nation law banning PBM ownership of pharmacies in 2025 explicitly cited the need to protect independent pharmacies from closure. A subsequent legal challenge resulted in a court-issued injunction, allowing PBM-owned pharmacies to continue operating while the law is under review. Regardless of the outcome, Arkansas’s action illustrates how quickly ambiguous closure statistics can translate into sweeping regulatory responses — responses that other states may consider even as the underlying evidence remains contested.
To be clear, some independent pharmacies do face genuine financial pressure from reimbursement rates, network design, and direct and indirect remuneration fees. The problem is not that these concerns are raised — it is that undifferentiated closure counts prevent policymakers from distinguishing struggling pharmacies that may need support from thriving businesses undergoing normal succession or acquisition.
This is not primarily a story about bad data or bad faith. It is a predictable outcome of relying on administrative signals that conflate exit mechanisms and drivers into a single, overly simplistic count. When closure statistics cannot distinguish retirement from distress, or acquisition from disappearance, they will reliably support the most alarmist interpretation — especially when that interpretation advances regulatory or political goals.
A better framework for analyzing pharmacy market exits
A clearer framework begins by separating mechanisms from drivers. Recognizing these distinctions matters for effective policy. When ownership transitions are counted as closures, analysts may conclude that pharmacy access is deteriorating even when services remain available. When retirements or acquisitions are labeled as failures, policymakers may focus on the wrong levers, and communities may be told they are losing pharmacies when they are instead experiencing succession or consolidation.
A more accurate understanding of pharmacy closures requires moving beyond raw counts to structured explanation: distinguishing ownership transitions from true exits, classifying exit drivers, and identifying which closures represent genuine access loss versus normal business succession or success. Precision is not a technical luxury here — it is the difference between solving the right problem and regulating the wrong one.
No Comments